The supervisory board of AM-Pharma currently consists of the following individuals:
Dr Greig served nearly three decades with pharmaceutical giant GlaxoSmithKline, most recently as President of SR One, GSK's Corporate Venture Group. Prior to joining SR One, he served as President of GSK's Pharmaceuticals International from 2003 to 2008 and also served on the GSK Corporate Executive Team. Dr Greig originally joined GSK (then SmithKline & French) in 1980 in the Departments of Tumor and Cell Biology. In 1991, following the merger with Beecham, he was appointed Vice President, Project Management. From 1993 to 1996, he served as Vice President and Director of Advanced Technologies in Genetics with special responsibility for managing collaborations with The Institute of Genomic Research and Human Genome Sciences. In 1996, Dr Greig joined SmithKline Beecham's European Pharmaceutical Operations as Vice President and Director of European Market Development, and was later appointed Managing Director and General Manager of SmithKline Beecham's UK Pharmaceuticals. Following the merger of SmithKline Beecham with GlaxoWellcome in 2000, he returned to the United States as Senior Vice President for Worldwide Business Development.
Bart Bergstein is Managing Partner at Forbion Capital Partners.
Bart Bergstein holds a degree in construction engineering from the Technical University of Eindhoven. At ABN AMRO he has gained broad international experience in finance and business administration. Bart Bergstein has a seven years’ experience in Venture Capital. Furthermore he holds supervisory board positions in Seed Capital Investment Fund 2, Licentec, Ardana Biosciences (Edinburgh) and is executive member of the board of the BioPartner Facility Fund.
Dr. Breiner is a venture capital investor with BB Biotech Ventures at Bellevue Group. Dr. Breiner has invested in numerous emerging biotech and pharma companies, in the US and Europe. His other current and past board assignments include Agendia BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc (now public), Glycart Biotechnology AG (acquired by Roche), Orthocon Inc, Pevion Biotech AG, and Vaximm AG. Dr. Breiner holds a PhD in molecular biology and, before joining Bellevue, he has been an investment manager at another European private equity firm and a business consultant with Booz, Allen & Hamilton. Dr. Breiner has received an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in Molecular Biology from the University of Heidelberg.
For over 20 years David has been involved in the successful start up and development of commercial businesses in both executive and non executive/chairman roles. He was instrumental in the successful development of venture capital businesses at 3i and MVM and most recently was a member of the executive management team that transformed Evotec into a CNS focused drug discovery company through a series of M&A transactions.
David holds a BSc in Genetics & Zoology from Sheffield University.
Ashok brings more than 20 years of international healthcare experience, focused primarily on Corporate & Business Development, Mergers & Acquisitions and Strategic Planning within leading multinational corporations where he was responsible for consumating a number of transformational deals and exits. His breadth of experience includes the unique opportunity of being involved in positions of significant influence across the sectors of functional foods, consumer health, pharmaceuticals and biotech. Additionally, he has built considerable network that enables global access to healthcare corporations, financial and high net worth communities.
Recent appointments comprise of Global Head of Corporate & Business Development at Serono, Senior Vice President and Global Head of Strategy and Business Development at Novartis Consumer Health; Vice President and Head of Strategy and Business Development at Baxter Europe, including senior positions at Roche, Andersen Consulting and Rhone-Poulenc. He holds a BA majoring in Economics & Commerce and a MBA from ESSEC. Ashok currently is Senior Vice President at Inventages Venture Capital and also serves as CEO and member of the board of directors at Horizon Science Pvt Ltd. Other board positions include Atonomics, Tanfield Foods, AM Pharma, ImmBio.
Rémi joined Kurma in September 2010, he was previously with CDC Innovation from 2000 to 2003 and with AGF Private Equity (now Idinvest Partners) from 2003 to 2010 where he was in charge of the development of the Life Sciences investment activity. During this period, Rémi serves on the board of several investee companies such as Adocia, Bioalliance Pharma (listed on Euronext), Domain Therapeutics, Integragen (listed on Alternext), Novagali Pharma (listed on Euronext), Prosensa and Zeland Pharma (listed on Nasdaq OMX Copenhagen. Remi has a MSc in molecular biology (Paris VI University) and MSc in finance and Innovation management (Masternova - AgroPariTech).
Dr. Joël Jean-Mairet is a partner and co-founder of Ysios Capital Partners. He has been Chairman of the board of Cellerix since 2007 and board observer at Boston-based Biovex Inc. (now: Amgen). Previously he co-founded Glycart Biotechnology AG in 2001 and was its CEO until the company was successfully sold to F. Hoffmann La-Roche in 2005. He has earned numerous awards including the Wall Street Journal Europe Innovation Award in 2001. He holds a masters degree in Biotechnology and earned his PhD from the Swiss Federal Institute of Technology (ETH) in Zurich.